Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 5 maj 2020
GÖTEBORG, 5 maj 2020 – Isofol Medical AB (publ), Org.nr. 556759-8064 (Nasdaq First North Premier Growth Market: ISOFOL), meddelar idag…
Isofols läkemedelskandidat arfolitixorin erhåller ännu ett Clinical Use Patent i USA
Göteborg, 5 maj 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), meddelade idag godkännande av…
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.